About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
News
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
PANCREATIC CANCER
Lixumistat shows promise as treatment for pancreatic cancer
Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an…
A signaling molecule released by blood vessel cells prompts cancer cells to grow and become resistant to treatment in glioblastoma, an aggressive type of…
GYNECOLOGICAL CANCER
Sempervirine stops ovarian cancer cell growth in preclinical studies
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of ovarian cancer cells in cell…
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
PANCREATIC CANCER
Combination treatment shows promise for pancreatic cancer PDAC
Treatment with certepetide in combination with standard therapies led to stable disease in most people with a type of pancreatic cancer known as…
The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx, Foundation Medicine’s companion diagnostic test to help identify if patients with pediatric low-grade…
Recent Posts
- Oral treatment for ovarian cancer put on FDA fast track
- J&J seeks approval in EU of Tecvayli-Darzalex for hard-to-treat myeloma
- I have goals and aspirations — not New Year’s resolutions
- 1st 4 patients in AML treatment combo trial show response
- FDA grants orphan drug status to ARB1002 for pancreatic cancer
